Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors. In an interview with CURE®, Dr. Eric K.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

Kineta is leveraging its deep expertise in innate immunity, and particularly myeloid cells, to develop innovative, first-in-class therapies with a primary focus on cancer. To date, immune-based ...

Infiltration of myeloid cells is a common feature of tumors that drives disease progression, but the function of JAM-A in this phenomenon and its impact on tumor-infiltrating myeloid cells is little ...

which can comprise up to 25 percent of the tumor’s mass. Myeloid cells invade tumors in response to diverse inflammatory stimuli produced by the tumor. Invading myeloid cells differentiate into ...

FRIDAY, Jan. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...